Mind Medicine (MindMed) Inc., a biopharmaceutical company focusing on treatments for brain health disorders, has announced the issuance of inducement grants to four newly hired non-executive employees. These grants consist of options to purchase a total of 128,750 common shares of the company. The options, effective from June 2, 2025, and June 9, 2025, depending on the employee's start date, are set at an exercise price equal to the closing price of MindMed's common shares on the last trading day before the grant date. The vesting schedule for these options spans four years, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in substantially equal monthly increments over the following three years, contingent upon continued employment. These inducement grants were approved by MindMed's Compensation Committee under NASDAQ's rules.